Alumina-promoted synthesis of N-aryl-1,2,4-triazoles from substituted hydrazines and imides
作者:William C. Neuhaus、Gustavo Moura-Letts
DOI:10.1016/j.tetlet.2016.09.086
日期:2016.11
Herein we report the highly efficient, environmentally friendly alumina-promoted synthesis of N-aryl-1,2,4-triazoles with a wide variety of substitution patterns from commercially available hydrazines with symmetrical and unsymmetrical imides. Aromatic hydrazines with a variety of substitution patterns provided the corresponding 1,2,4-triazoles in very high yields. Unsymmetrical imides with a wide
A fundamental wave (15) is caused to enter a Cerenkov-radiation type optical wavelength converter device (10) which is formed of a single-crystal organic nonlinear optical material (11) of an orthorhombic system of mm2 point group disposed in a cladding (12) as a waveguide and a wavelength-converted wave such as a second harmonic whose wavelength is within the range of 430 to 500nm is extracted. The wavelength of said fundamental wave (15) is selected so that the wavelength of the wavelength-converted wave (15') becomes longer than the absorption edge of the organic nonlinear optical material by at least 30nm. The fundamental wave (15) is linearly polarized in the direction of the x-optic-axis or the y-optic-axis of the crystal of the organic nonlinear optical material and then caused to enter the optical wavelength converter device (10), and a wavelengthconverted wave (15') which is linearly polarized in the z-optic-axis of the crystal is extracted.
使基波(15)进入塞伦科夫辐射型光波长转换装置(10),该装置由配置在作为波导的包层(12)中的 mm2 点群正交系单晶有机非线性光学材料(11)构成,并提取波长在 430 至 500nm 范围内的二次谐波等波长转换波。选择所述基波(15)的波长,使波长转换波(15')的波长比有机非线性光学材料的吸收边缘至少长 30 纳米。基波(15)沿有机非线性光学材料晶体的 x 光轴或 y 光轴方向线性偏振,然后进入光波长转换装置(10),提取沿晶体的 z 光轴线性偏振的波长转换波(15')。
BMP-signal-inhibiting compound
申请人:RIKEN
公开号:US10954216B2
公开(公告)日:2021-03-23
The present invention relates to novel and excellent small-molecule-compounds that specifically antagonize BMP signal pathways, and these compounds can be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus can be used to treat diseases or pathological symptoms related to BMP signal pathway including inflammation, cardiovascular diseases, hematopoietic diseases, cancer, osteodystrophia, or the like, particularly, fibrodysplasia ossificans progressiva, and the present invention relates to provision of a pharmaceutical and pharmacological agent used for specifically antagonizing the BMP signal pathways and acting on the BMP signal pathways in the prevention and treatment or experimental application since the compounds can be beneficial for regulating cell differentiation and/or cell proliferation.